The firm is a U.S.-based venture capital investor managing multiple investment vehicles with complementary investment strategies. Through its healthcare-focused fund, the firm primarily invests in Seed and Series A companies, making initial equity investments ranging from $250K–$3M. The firm prefers to lead financing rounds and requires board representation, although co-investments may also be considered. Through a separate diversified investment vehicle, the firm makes smaller investments of approximately $100K–$250K across a broader range of industries and development stages, including later-stage and Pre-IPO opportunities. The firm primarily invests in the United States and may consider international companies that have completed applicable regulatory processes.

The firm’s healthcare investment strategy focuses on healthtech, medical technology, and biotechnology, with particular interest in in vitro diagnostics, software-based digital health solutions, gene editing, and cell therapies. Within medical devices and diagnostics, the firm considers Class I and 510(k) regulatory pathways but generally excludes devices requiring Premarket Approval (PMA). The firm prioritizes revenue-generating companies demonstrating commercial scalability, repeat customers, and recurring business opportunities. The firm’s diversified investment strategy also considers companies across artificial intelligence, technology, aerospace, defense, and other high-growth industries.

From a company and management team perspective, the firm takes a founder-friendly approach and does not impose strict management team requirements. For healthcare investments, the firm emphasizes commercial traction, scalable business models, and demonstrated customer demand. The firm generally prefers to lead healthcare financing rounds and requires a board seat to maintain active governance involvement. Investment requirements and governance expectations under the firm’s diversified investment strategy may vary depending on the opportunity.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

The firm is a Europe-based venture capital investor focused exclusively on therapeutics, with an investment team spanning Europe, North America, and the Middle East. The firm typically makes several new investments annually and invests from Seed through Series B, with commitments of up to approximately $5M–$6M per company. The firm is flexible regarding financing structures and considers traditional equity investments, SAFEs, and convertible notes. The firm can co-lead financing rounds or participate in investment syndicates. The firm invests globally, with significant investment activity in North America.

The firm invests exclusively in therapeutics and has a particular preference for advanced therapeutic modalities, especially genetic medicines. The firm is broadly indication-agnostic and considers a wide range of therapeutic approaches on a case-by-case basis. The firm focuses on preclinical-stage companies developing differentiated therapeutic technologies with strong scientific foundations and the potential to address meaningful unmet medical needs. While advanced modalities represent a priority, the firm remains open to other therapeutic technologies demonstrating compelling scientific and commercial potential.

From a company and management team perspective, the firm does not impose specific requirements regarding leadership composition or prior entrepreneurial experience. The firm seeks companies developing differentiated therapeutic programs with credible scientific rationale and opportunities for significant value creation. The firm is comfortable participating alongside other investors and may take a co-lead role depending on the financing opportunity.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

The firm is an impact-oriented venture capital investor focused on advancing innovative healthcare technologies with significant clinical and commercial potential. The firm is developing a dedicated healthcare investment fund targeting approximately $150M in commitments and primarily invests at the Series A stage. The firm deploys equity capital to support companies approaching important clinical, regulatory, or commercial milestones. The firm primarily targets opportunities in the United States, with selective interest in Europe and Israel.

The firm focuses on oncology therapeutics, cardiovascular medical devices, and other differentiated healthcare innovations. Within oncology, the firm is modality-agnostic and evaluates novel therapeutic approaches with strong scientific rationale and clearly defined development pathways. The firm generally prefers therapeutic programs approaching IND clearance or entering early clinical development. Within medical devices, the firm has a particular interest in cardiovascular technologies and prioritizes FDA-regulated products requiring Premarket Approval (PMA), while remaining open to select 510(k) devices. Medical device companies are generally expected to have a functional prototype. The firm may also consider opportunities outside its core sectors when technologies demonstrate exceptional innovation and substantial growth potential.

From a company and management team perspective, the firm seeks experienced leadership teams capable of executing clinical development, regulatory, and commercialization strategies. The firm prioritizes strong scientific foundations, credible development plans, and clear pathways toward meaningful patient impact. The firm takes an engaged investment approach and supports portfolio companies through strategic guidance, governance participation, and access to clinical, regulatory, and industry networks.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

The firm is the corporate venture capital arm of a diversified global company with established businesses across healthcare, advanced materials, and imaging technologies. The firm manages a dedicated life sciences investment fund focused on innovative technologies with strong commercial and strategic potential. Initial investments typically begin in the several-hundred-thousand-dollar range, with capacity for follow-on investments. The firm primarily targets Series A and Series B companies and generally participates as a co-investor. The firm invests globally, with opportunities evaluated based on their alignment with the parent company’s healthcare and life sciences businesses.

The firm invests across therapeutics, diagnostics, medical technologies, and drug discovery enabling technologies. Areas of particular interest include regenerative medicine, cell therapies, small molecules, and innovative R&D platforms. Within diagnostics and medical technology, the firm evaluates medical imaging systems, endoscopy, ultrasound, in vitro diagnostics, veterinary diagnostics, and AI-enabled diagnostic technologies. The firm is broadly opportunistic across therapeutic indications and prioritizes technologies that complement its existing capabilities in healthcare, biotechnology, and life sciences. The firm is comfortable evaluating early-stage technologies, including preclinical therapeutic programs and products still under development.

From a company and management team perspective, the firm does not impose specific requirements regarding team composition or organizational maturity. The firm seeks differentiated technologies with strong growth potential and opportunities for strategic collaboration. Beyond equity investments, the firm may explore research collaborations, licensing, and other strategic partnerships that leverage its parent company’s research, manufacturing, and commercialization capabilities.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.